| Literature DB >> 9871445 |
L Verhagen Metman1, P Del Dotto, P J Blanchet, P van den Munckhof, T N Chase.
Abstract
In animal models of Parkinson's disease (PD), glutamate antagonists diminish levodopa (LD)-associated motor fluctuations and dyskinesias. We sought to investigate if these preclinical observations can be extended to the human disease, by evaluating the effects of three non-competitive NMDA antagonists (dextrorphan, dextromethorphan and amantadine) on the motor response to LD in patients with advanced PD. In four separate trials, adjuvant therapy with these drugs reduced LD-induced dyskinesias and motor fluctuations. These findings support the view that drugs acting to inhibit glutamatergic transmission at the NMDA receptor can ameliorate LD associated motor response complications.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9871445 DOI： 10.1007/bf01345246
Source DB: PubMed Journal: Amino Acids ISSN： 0939-4451 Impact factor: 3.520